Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)

Trial Profile

Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Nusinersen (Primary)
  • Indications Spinal muscular atrophy
  • Focus Expanded access; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 07 Nov 2016 Status changed from planning to recruiting, according to a Biogen and Ionis Pharmaceuticals media release.
    • 07 Nov 2016 According to a Biogen and Ionis Pharmaceuticals media release, the company will continue to explore where and when the EAP may be broadened to include patients with later-onset SMA (consistent with Type 2).
    • 10 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top